China’s economic growth has increased demand for pharmaceutical imports as budgets for healthcare expand. Imports have grown by 12% annually in the five years to September 30 to reach $16 billion, with the largest consignees including Zuellig, AstraZeneca and Bayer. U.S. imports are 18x larger on a per person basis. Supplies have been led by shipments from Germany, which have climbed 24% over the past five years, though the U.S. is catching up with a 27% surge in the past quarter on a year earlier. China is also building up its export industry, though these were just $3 billion in the pa...